尿激酶治疗急性心肌梗塞疗效观察

Effect of Treatment of Acute Myocardial Infarction with Urokinase

观察尿激酶 ( UK)在急性心肌梗塞 ( AMI)治疗中的溶栓效果和不良反应。 1 994年 3月至 1 999年 1 0月对 1 68例 AMI患者用 1 0 0万 IU或者 1 50万 IU进行溶栓治疗 ,观察溶栓再通率、急性期死亡率 ( 3 5d)、并发症以及不良反应发生率等。结果表明 (与对照组 1 2 3例比较 )溶栓再通率为 66.1 % ( P<0 .0 0 1 ) ,死亡率 7.7% ( P<0 .0 0 1 ) ,脑出血1 .2 % ,上消化道出血 2 .4 % ,轻度出血 2 .4 % ,未发生过敏反应。提示 UK为治疗 AMI有效、安全的溶栓药物。

To investigate thrombolytic effects and untoward effects of treatment of acute myocardial infarction (AMI) with urokinase (UK),from March,1994 to October, 1999,168 cases of AMI patients were underwent thrombolytic therapy with either 10 6 IU or 1.5×10 6 IU of urokinase and the rate of thrombolytic and re open,dead rate during acute phase (35days),complications and untoward effects were observed and calculated. The results showed a higher thrombolytic re open rate (66.1%,P<0.001) with UK treatment, as compared to the control group (123 cases),lower mortality rate (7.7%,P<0.001), less encephalorrhage (1.2%),less hemorrhage of upper digestive tract (2.4%), and no allergic reaction was observed. Indicating that urokinase is an effective,safe drug for treatment of AMI.